

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

09/101,413

Filing Date

July 10, 1998

First Named Inventor	_____
-----------------------------	-------

Hans Josef Stauss

Group Art Unit

Examiner Name *Fuat D*

Attorney Docket Number

RPMS 102

Sheet	1	of	1
-------	---	----	---

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner's Signature	<i>E. Webb</i>	Date Considered	10/7/00
-------------------------	----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/101,413
Filing Date	July 10, 1998
First Named Inventor	Hans Josef Stauss, et al.
Group Art Unit	1344
Examiner Name	Not Yet Assigned
Attorney Docket Number	RPMS 102

Sheet	1	of	6
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		✓	WO 91/04317	PCT		4/4/91		
		✓	WO 9201459	PCT		2/6/92		
		✓	WO 92/05794	PCT		4/16/92		
		✓	WO 93/17095	PCT		9/2/93		
		✓	WO 94/21287	PCT		9/29/94		
		✓	WO 95/04817	PCT		2/16/95		
		✓	WO 95/18969	PCT		7/13/96		

Examiner's
Signature

Fredd

Date	
Considered	

10/7/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/101,413
		Filing Date	July 10, 1998
		First Named Inventor	Hans Josef Stauss, et al.
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 3 of 6	Attorney Docket Number	RPMS 102	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
ASZ	✓	Alexander, et al., "Differential Transport Requirements of HLA and H-2 Class I Glycoproteins," <i>Immunogenetics</i> 29:380-388 (1989).	
	✓	Bakker, et al., "Melanocyte Lineage-Specific Antigen gp100 is Recognized by Melanoma-Derived Tumor-Infiltrating Lymphocytes," <i>J. Exp. Med.</i> 179:1005-1009 (1994).	
	✓	Boël, et al., "BAGE: a New Code Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes," <i>Immunity</i> 2(2):167-175 issn. 1074-7613 (1995).	
	✓	Chung, et al., "Functional Three-Domain Single-Chain T-Cell Receptors," <i>Proc. Natl. Acad. Sci. USA</i> 91:12654-12658 (1994).	
	✓	Cox, et al., "Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines," <i>Science</i> 264:716-719 (1994).	
	✓	Eshhar, et al., "Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-Binding Domains and the (or . Subunits of the Immunoglobulin and T-Cell Receptors," <i>Proc. Natl. Acad. Sci. USA</i> 90(N2): 720-724 (1993).	
	✓	Faber, et al., "Generation of Leukemia-reactive Cytotoxic T Lymphocyte Clones from the HLA-identical Bone Marrow Donor of a Patient with Leukemia," <i>J. Exp. Med.</i> 176(5):1283-1289 (1992).	
	✓	Falkenberg, et al., "Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow Transplantation," <i>J. Immunotherapy</i> 14(4):305-309 issn. 1053-8550 (1993).	
	✓	Fidler & Nicholson, "Brief Communication: Organ Selectivity for Implantation Survival and Growth of B16 Melanoma Variant Tumor Lines," <i>J. Natl. Cancer Inst.</i> 57:1199-1202 (1976).	
	✓	Finer, et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," <i>Blood</i> 83:43-50 (1994).	
	✓	Gagliardi, et al., "Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes <i>in vitro</i> ," <i>Intl. Immunol.</i> , 7(11):1741-1752 (1995).	

Examiner's Signature	<i>E. Smith</i>	Date Considered	10/7/00
----------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/101,413
		Filing Date	July 10, 1998
		First Named Inventor	Hans Josef Stauss, et al.
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 4 of 6	Attorney Docket Number	RPMS 102	
OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
HFE	✓	Goldman, "Allogenic Bone Marrow Transplantation: State of the Art and Future Directions," Bone Marrow Transplant 1:133-134 (1989).	
	✓	Heath, et al., "Peptide-dependent recognition of H-2K ^b by alloreactive cytotoxic T lymphocytes," Nature, 341(6244):749-752 (1989).	
	✓	Hwu, et al., "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor Chain," J. Exp. Med. 178:361-366 (1993).	
	✓	Kast, et al., "Eradication of Adenovirus E1-Induced Tumors by E1A-Specific Cytotoxic T Lymphocytes," Cell 59(4):603-614 (1989).	
	✓	Kawakami, et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection," Proc. Natl. Acad. Sci. USA 91(14):6458-6462 (1994).	
	✓	Kawakami, et al., "Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor," Proc. Natl. Acad. Sci. USA 91(9):3515-3519 (1994).	
	✓	Kawakami, et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restricted Tumor Infiltrating Lymphocytes," J. Exp. Med. 180:347-352 (1994).	
	✓	Ljunggren & Kärre, "Host Resistance Directed Selectively Against H-2-Deficient Lymphoma Variants," J. Exp. Med. 162:1745-1759 (1985).	
	✓	Moritz, et al., "Cytotoxic T Lymphocytes with a Grafted Recognition Specificity for ERBB2-Expressing Tumor Cells," Proc. Natl. Acad. Sci. USA 91:4318-4322 (1994).	
	✓	Nixon & McMichael, "Cytotoxic T-Cell Recognition of HIV Proteins and Peptides," AIDS 5(9):1049-1059 (1991).	
HFE	✓	Nowak, et al., "Antigenic Oscillations and Shifting Immunodominance in HIV-1 Infections," Nature 375(6532):606-611 (1995).	
Examiner's Signature	Date Considered		10/7/98

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09,101/413
		Filing Date	July 10, 1998
		First Named Inventor	Hans Josef Stauss, et al.
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 5 of 6	Attorney Docket Number	RPMS 102	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
JS	✓	Riddell, et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," <i>Science</i> 257(5067):238-241 (1992).	
	✓	Roberts, et al., "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8 + T Lymphocytes Armed with Universal T-Cell Receptors," <i>Blood</i> 84:2878-2889 (1994).	
	✓	Rojo, et al., "Peptide-Mediated Allo-Recognition of HLA-B27 by Cytotoxic T Lymphocytes," <i>Int. J. Cancer: Suppl.</i> 6:10-13 (1991).	
	✓	Stauss and Dahl, "Cellular Oncogenes for Tumour Immunity: Immunotherapy," <i>Tumour Immunology</i> , Dalglish/Browning, Chapter 7 (1995).	
	✓	Theobald, et al., "Targeting p53 as a General Tumor Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 92:11993-11997 (1995).	
	✓	Torpey, et al., "Effects of Adoptive Immunotherapy with Autologous CD8 + T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity," <i>Clin. Immunol. Immunopathol.</i> 68(3):263-272 (1993).	
	✓	Traversari, et al., "A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E," <i>J. Exp. Med.</i> 176:1453-1457 (1992).	
	✓	van der Bruggen, et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <i>Science</i> 254:1643-1647 (1991).	
	✓	van Lochem, et al., "In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities," <i>Bone-Marrow-Transplantation</i> 10(2):181-183 (1992).	
	✓	Walker & Plata, "Editorial Review: Cytotoxic T Lymphocytes Against HIV," <i>AIDS</i> 4(3):177-184 (1990).	
JS	✓	Wölfel, et al., "Two Tyrosinase Nonapeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes," <i>Eur. J. Immunol.</i> 24:759-764 (1994).	
Examiner's Signature	E. Wölfel		Date Considered 10/7/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+